0001867096-24-000041.txt : 20240401 0001867096-24-000041.hdr.sgml : 20240401 20240401174509 ACCESSION NUMBER: 0001867096-24-000041 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240315 FILED AS OF DATE: 20240401 DATE AS OF CHANGE: 20240401 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kong Garheng CENTRAL INDEX KEY: 0001435183 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40880 FILM NUMBER: 24811370 MAIL ADDRESS: STREET 1: 712 COLLEGE AVENUE CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Xeris Biopharma Holdings, Inc. CENTRAL INDEX KEY: 0001867096 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 871082097 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1375 WEST FULTON STREET, SUITE 1300 CITY: CHICAGO STATE: IL ZIP: 60607 BUSINESS PHONE: 844-445-5704 MAIL ADDRESS: STREET 1: 1375 WEST FULTON STREET, SUITE 1300 CITY: CHICAGO STATE: IL ZIP: 60607 4 1 wk-form4_1712007900.xml FORM 4 X0508 4 2024-03-15 0 0001867096 Xeris Biopharma Holdings, Inc. XERS 0001435183 Kong Garheng C/O XERIS BIOPHARMA HOLDINGS, INC. 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 1 0 0 0 0 Common Stock 2024-03-15 4 J 0 6474 A 114144 D Keveyis Sales 2023 Milestone achieved resulting in the settlement of the related Contingent Value Right ("CVR") in shares of Xeris Biopharma Holdings, Inc. (the "Company")'s Common Stock. The reporting person's right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on October 5, 2021, the effective time of the Merger (as defined below), pursuant to the transaction agreement dated as of May 24, 2021 by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), where HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge, and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger"). The number of shares of Common Stock for the CVR is equal to the product (A) $0.25 divided by the volume weighted average price for the Company's Common Stock as reported by Nasdaq for the ten (10) Trading Days immediately prior to October 5, 2021 and (B) the number of CVRs held by the holder as reflected on the CVR Register. /s/ Beth Hecht, as Attorney-in-Fact 2024-04-01